So looking forward to this with many excellent international speakers presenting data from #ASCO & #EHA2024 on Friday 28th June & always a joy when Anna Sureda is Chair & moderating with Wendy 🎉 Register: us06web.zoom.us/webinar/regist…

Graham Collins Wow, you weren't wrong it's a noticeably more bulky edition! Great work, I always highly recommend this series, it's so useful as an MDT colleague!

More jobs in Oxford! Are you an SpR or more junior doc with a keen interest in haematology and interested in clinical research experience? See advert for early phase trial fellow in lymphoid disorders. Interesting and varied job with a fantastic team. healthjobs.bmj.com/job/354630/cli…

Not the usual post from me. But if you’re interested in the ‘brilliant billion’ - what the earth was doing billions of yrs ago, ancient mountain ranges & oceans etc. check out this podcast by my amazing brother Alan Collins! open.spotify.com/episode/1KMKgq…

Front line treatment of Hodgkin Lymphoma with PET-adapted BrECADD vs escBEACOPP. BrECADD wins the day. Can it be beaten…? #lymsm thelancet.com/journals/lance…

Typically excellent analysis of the modern treatment landscape for Hodgkin lymphoma by Andrew M. Evens, DO, MBA, MSc. Last point very well made - need now to use emerging tools eg circulating biomarkers, MTV etc to better personalise treatment with lifelong impact of therapy in view.

5y outcomes SOC Axi-Cel: US real world data, Jain et al • All 3rd+ line, 298 leucopheresed pts • 5y PFS/OS 29%/40% • 5y NRM 16% (infn/ 2nd malig dominant) • NRM higher in > 60y Worrying NRM. Could this be ⬇️ when used 2nd line (less prior Rx)? #lymsm ascopubs.org/doi/10.1200/JC…

So… often I get asked to make my posts more accessible to non-medics. I thought I might try doing this on Instagram. Never used Insta before so should be interesting. Just search for ‘lymphomaprof’!

Getting ready to review some patient information sheets for a trial. Lime cordial in hand. Life of a PI.

Nice data from Brinkman et al showing co-administration of anti-CD20 bispecific antibody with anti-CD19 CAR T-cells enhanced efficacy in vitro and in in vivo CLL model. Associated with expansion of both endogenous T-cells and CAR T-cells. #lymsm ashpublications.org/blood/article-…

Risk score for WM - age - LDH - albumin Nice and simple! 5y OS from 55% to 93%. But pts were diagnosed 1997-2017. Will this hold when more BTKi therapy being used? A common problem for risk scores. #lymsm ascopubs.org/doi/10.1200/JC…

I have to admit to not reading this yet. But I love the title!

Whilst underpowered it’s the largest randomised trial we will get for this and has shaped our practise. PMBCL in CMR after 1L immunochemo - no benefit of radiotherapy observed. The question now is what to do with the Deauville 4 responses.

Great work from friend and colleague Jaimal Kothari - a WM guru.

Don’t miss out! There is still time to sign up - but not for much longer. Really looking forward to seeing you there for some stimulating discussions around some fascinating lymphoma related topics.

#Hematology Pirtobrutinib, a non-covalent BTK inhibitor in patients with B-cell malignancies: analysis of the #Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study - ⁦The Lancet Haematology⁩ #lymsm thelancet.com/journals/lanha…

Look at those lawn stripes Dr francesca kinsella

Enjoying a lovely day at Windsor Castle - Oxford Haematology cricket team vs Royal Household Cricket Club! We need 128 to win. Team led by ace cricketer Jaimal Kothari

Cricket hero Manil Subesinghe 🇬🇧🇱🇰 getting ready to bat!

A fab day. Did we win? Let’s just say we raised a bunch of money for haematology @OUH_research and so I think we were all winners!